Peptide Drug Development — From Discovery to Clinic
Peptide drug development is moving rapidly from academic discovery into clinical development. Yet most researchers outside industry rarely encounter the regulatory lens that determines whether a promising peptide can ever reach patients. This hub is your roadmap: it brings together the scientific, regulatory, and practical steps that shape peptide drug development.
Our goal is not to limit creativity in discovery. Basic research must remain bold and exploratory. But awareness of Chemistry, Manufacturing, and Controls (CMC) can help researchers avoid dead-ends, strengthen grant applications, and make translational projects more credible.
Peptide Drug Development Hub — Who is this hub for?
👩🔬 PhD Students & Postdocs: Learn how to design experiments and report results in a way that keeps future development open, without limiting discovery creativity.
🎓 PIs & Grant Writers: Show funders that your lab’s results are framed in a translational context — a key credibility boost.
🚀 Biotech Founders & Translational Researchers: See how early bench data connects to specifications, stability, regulatory expectations, and investor due diligence.
What you’ll find Here?
This hub links you to detailed guides on each critical step in the journey:
- Why CMC thinking matters from the earliest stages of discovery.
- Who regulates what: EMA, FDA, ICH — and how their roles connect.
- Bench-level actions: how to assess identity, purity, impurities, counter-ions, stability.
- From lab data to proto-specs: turning academic results into development-ready packages.
- Deep dives into impurities, counter-ions, and stability mechanisms.
Each guide is designed to be actionable, accessible, and interconnected — so you can move from the big picture to bench-level details without losing sight of the full pipeline.
The Bigger Picture
Think of this page as the entry point into peptide drug development. It frames the journey from:
Discovery → CMC → Nonclinical → Clinical → Regulatory Approval
Nonclinical and clinical aspects (toxicology, trial design, endpoints) are touched only briefly, since they apply across drug classes. Our focus is on the CMC core of peptide drug development — the part most often overlooked in academic contexts, but decisive for whether a peptide becomes a medicine.
Your Roadmap: Key Guides in Peptide Drug Development
📖 CMC in Peptide Discovery: Why It Matters? — See why early awareness of identity, purity, impurities, and stability keeps discoveries open for translation and investment.
📖 Peptide Drug Development Regulations: EMA, FDA, and ICH — Understand the global regulatory landscape and how agencies fit together in peptide development.